Your browser doesn't support javascript.
loading
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
Park, Jong-Ho; Woo, Young Min; Youm, Emilia Moonkyung; Hamad, Nada; Won, Hong-Hee; Naka, Kazuhito; Park, Eun-Ju; Park, June-Hee; Kim, Hee-Jin; Kim, Sun-Hee; Kim, Hyeoung-Joon; Ahn, Jae Sook; Sohn, Sang Kyun; Moon, Joon Ho; Jung, Chul Won; Park, Silvia; Lipton, Jeffrey H; Kimura, Shinya; Kim, Jong-Won; Kim, Dennis Dong Hwan.
Afiliação
  • Park JH; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
  • Woo YM; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
  • Youm EM; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
  • Hamad N; Department of Haematology, St Vincent's Hospital, University of New South Wales, Sydney, Australia.
  • Won HH; Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Samsung Medical Center, Seoul, Korea.
  • Naka K; Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Park EJ; Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.
  • Park JH; Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.
  • Kim HJ; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kim SH; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kim HJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
  • Ahn JS; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
  • Sohn SK; Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea.
  • Moon JH; Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea.
  • Jung CW; Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Park S; Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Lipton JH; Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
  • Kimura S; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Kim JW; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea. kimjw@skku.edu.
  • Kim DDH; Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Samsung Medical Center, Seoul, Korea. kimjw@skku.edu.
Leukemia ; 33(6): 1439-1450, 2019 06.
Article em En | MEDLINE | ID: mdl-30555164
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Biomarcadores Tumorais / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Oxo-Ácido-Liases / Mutação Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Biomarcadores Tumorais / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Oxo-Ácido-Liases / Mutação Idioma: En Ano de publicação: 2019 Tipo de documento: Article